Data Asset · Updated Monthly
GLP-1 Price Index
Last verified Jul 31, 2026 · August 2026 edition
This is the dataset behind the GLP-1 Cost Tracker: the published monthly list price for every legal way to get Wegovy, Zepbound, and Foundayo — savings card, self-pay, patient assistance, Medicare, and Medicaid — each figure carrying an as-of date and a link to its primary source. No other site maintains this. We take no money from providers or manufacturers — members fund the research.
Master Table
Every legal channel, priced and dated
Each row is one access channel. "Monthly list price" is the figure published by the source on its as-of date; ranges reflect dose or refill-timing tiers noted in the eligibility column. A price of "Plan-specific — no single published price" means the channel has no single posted number because the cost depends on your plan.
| Drug | Channel | Monthly list price | As-of date | Source URL | Eligibility / notes | Order confirmation required | Order confirmation source URL | Auto-refill default | Auto-refill source URL | Cancellation method | Cancellation source URL | FDA warning letter | FDA warning letter date | FDA warning letter URL | Billing verified as-of |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide (Wegovy) | Wegovy savings card (commercial insurance) | $25/mo | Jul 31, 2026 | Source ↗ | Eligible commercial insurance only — Medicare, Medicaid and other government plans are excluded. Savings are capped at $100/month. | ||||||||||
| Tirzepatide (Zepbound) | Zepbound savings card (commercial insurance) | $25/mo | Jul 31, 2026 | Source ↗ | Commercial insurance only; applies to the single-dose pen. The savings card expires 12/31/2026 and caps annual savings at $1,300. | ||||||||||
| Foundayo (oral orforglipron) | Your plan copay + Lilly savings card | Plan-specific — no single published price | Jul 31, 2026 | Source ↗ | We could not verify a single published commercially-insured price for Foundayo — it depends on your plan and the live savings offer. | ||||||||||
| Semaglutide (Wegovy) | Wegovy self-pay (NovoCare) | $349/mo (0.25–2.4 mg pen) | Jul 31, 2026 | Source ↗ | Intro price is $199/mo for the first 2 months (0.25/0.5 mg), then $349/mo. The 7.2 mg pen is $399/mo; oral Wegovy self-pay starts at $149/mo. | ||||||||||
| Tirzepatide (Zepbound) | Zepbound self-pay (LillyDirect) | $299–$449/mo | Jul 31, 2026 | Source ↗ | You must refill within 45 days of delivery or the price reverts to $499–$699. Single-dose vials are $299; KwikPens are $399–$449 by dose. | ||||||||||
| Foundayo (oral orforglipron) | Foundayo self-pay (LillyDirect) | $149–$299/mo | Jul 31, 2026 | Source ↗ | $149/mo for the 0.8 mg starter dose, rising to $299/mo for 5.5 mg and up. You must refill within 45 days of delivery or the price reverts to as much as $349/mo — the same refill-window structure as Zepbound. | ||||||||||
| Semaglutide (Wegovy) | Novo Nordisk Patient Assistance Program | $0 | Jul 31, 2026 | Source ↗ | Uninsured with income limits only — not available if you have any commercial or government drug coverage. Application and approval are required before you receive medication. | ||||||||||
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Medicare GLP-1 Bridge | $50/mo | Jul 31, 2026 | Source ↗ | Zepbound is covered as the KwikPen only. Requires Part D; you can't already be getting a GLP-1 through Part D; excludes people diagnosed with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. The $50 copay does not count toward your deductible or out-of-pocket cap. Runs July 1, 2026 – December 31, 2027. | ||||||||||
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Standard Part D (outside the Bridge) | Plan-specific — no single published price | Jul 31, 2026 | Source ↗ | If you qualify for one of these medical indications, this is not weight-loss coverage and different plan rules apply. | ||||||||||
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | State Medicaid coverage | $0–low copay | Jul 31, 2026 | Source ↗ | Coverage is state-by-state and, where offered, requires prior authorization and BMI criteria. As of January 2026 only about 13 state Medicaid programs cover GLP-1s for weight loss. |
Billing Practices
How each channel handles orders, refills, and cancellations
How to read this table. Each value below is a dated, sourced statement of fact — not a grade, score, ranking, or safety rating. We report what a channel's own published pages say and nothing more.
- Order confirmation, auto-refill default, and cancellation method were checked only against each vendor's published terms of service, refund policy, and FAQ pages. We did not create accounts, enter payment details, or place orders. Where the published terms are silent, the value is “Not verified” — never inferred or guessed.
- FDA warning letter was checked against the FDA warning-letter database at fda.gov/safety/warning-letters (searched for “telehealth” and each company name). A warning letter records the FDA's alleged violations; it is not a court finding or a determination of guilt, and a company may have already corrected the claims at issue. “No public letter found” means no letter naming that company was visible in the database on the date checked — not that one could never exist.
- Every non-“Not verified” value links to the exact page it came from. All billing fields were last verified on Aug 9, 2026.
Verified vs. “Not verified” across 10 channels — Order confirmation: 3/10 · Auto-refill default: 0/10 · Cancellation method: 0/10 · FDA warning letter (“Yes”): 0/10.
| Drug | Channel | Order confirmation required | Auto-refill default | Cancellation method | FDA warning letter |
|---|---|---|---|---|---|
| Semaglutide (Wegovy) | Wegovy savings card (commercial insurance) | Not verified | Not verified | Not verified | No public letter found |
| Tirzepatide (Zepbound) | Zepbound savings card (commercial insurance) | Not verified | Not verified | Not verified | No public letter found |
| Foundayo (oral orforglipron) | Your plan copay + Lilly savings card | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy) | Wegovy self-pay (NovoCare) | Yes Source ↗ | Not verified | Not verified | No public letter found |
| Tirzepatide (Zepbound) | Zepbound self-pay (LillyDirect) | Yes Source ↗ | Not verified | Not verified | No public letter found |
| Foundayo (oral orforglipron) | Foundayo self-pay (LillyDirect) | Yes Source ↗ | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy) | Novo Nordisk Patient Assistance Program | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Medicare GLP-1 Bridge | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | Standard Part D (outside the Bridge) | Not verified | Not verified | Not verified | No public letter found |
| Semaglutide (Wegovy); Tirzepatide (Zepbound); Foundayo (oral orforglipron) | State Medicaid coverage | Not verified | Not verified | Not verified | No public letter found |
What Changed This Month
August 2026 — no cheapest-path price moved
We re-verified every channel at its primary source on July 31, 2026. No tracked cheapest-path price changed this cycle — "no change" is a finding, not a gap. Below are the one display clarification and the two state-Medicaid developments we logged, each with one plain-English line on what it means for patients.
| Item | Old | New | What it means for patients |
|---|---|---|---|
| All tracked cheapest-path prices | July 2026 figures | No change | Re-verified every channel on July 31, 2026: both $25/mo savings cards, Wegovy self-pay ($349/mo, $199 intro), Zepbound self-pay ($299–$449/mo), the $50/mo Medicare Bridge, and the $0 patient-assistance path all held steady from July. |
| Foundayo self-pay (LillyDirect) | $149–$349/mo | $149–$299/mo | No price move — a display fix. The everyday self-pay price tops out at $299/mo (5.5 mg and up); $349 is the reversion price if you miss the 45-day refill window, so we now show it the same way as Zepbound. |
| Massachusetts Medicaid (weight-loss) | Covered | Ended Jul 1, 2026 | Massachusetts stopped covering GLP-1s prescribed solely for weight loss on July 1, 2026 (diabetes and cardiovascular coverage continue). Massachusetts is not one of the states we mark as covered, so no tracked price changed. |
| Rhode Island Medicaid (weight-loss) | Covered | Ending Oct 1, 2026 | Rhode Island’s enacted FY2027 budget ends GLP-1 coverage for weight management on October 1, 2026 (diabetes coverage stays). It has no patient impact yet and does not change a tracked price this month. |
Methodology
How this index is built and verified
Every price in this index is a list price published by a primary source: the manufacturer’s own self-pay and savings pages (Novo Nordisk / NovoCare and Eli Lilly / LillyDirect), each program’s official terms, and government coverage pages (CMS for the Medicare GLP-1 Bridge, and KFF’s state Medicaid tracking). We do not use aggregator estimates, discount-card screenshots, or unverifiable figures. "Verified" means one of us opened the source on the as-of date shown and confirmed the number against it; any figure we cannot confirm is flagged and left out rather than guessed. We re-check every source at least monthly, and sooner when a program announces a change. These are list prices — your actual out-of-pocket cost can differ with insurance, eligibility, dose, and refill timing, all noted in the eligibility column.
We take no money from providers, pharmacies, or manufacturers, and this page carries zero affiliate links. Members of the GLP-1 Cost Tracker fund the research.
Cite this page
- Publisher
- GLP-1 Answers
- Title
- GLP-1 Price Index
- Last verified
- Jul 31, 2026
GLP-1 Answers. GLP-1 Price Index. Last verified Jul 31, 2026. https://www.glp1answers.org/data/glp1-price-index
Download & formats
The full dataset is available as a CSV generated from the same source data as the table above — columns match exactly.
Download glp1-price-index.csv